Search alternatives:
aromatic decrease » dramatic decrease (Expand Search)
somatic decrease » dramatic decrease (Expand Search)
small decrease » small increased (Expand Search)
Showing 521 - 540 results of 2,241 for search '((aromatic decrease) OR (((somatic decrease) OR (small decrease))))', query time: 0.25s Refine Results
  1. 521
  2. 522
  3. 523
  4. 524
  5. 525
  6. 526
  7. 527
  8. 528
  9. 529
  10. 530
  11. 531
  12. 532
  13. 533
  14. 534
  15. 535
  16. 536
  17. 537

    Table 3_NK cell-derived extracellular vesicles enhance cytotoxicity and immune cell recruitment in non-small cell lung cancer.xlsx by Joanna Palade (17712960)

    Published 2025
    “…Introduction<p>Immune-based agents, especially Immune Checkpoint Inhibitors (ICI), are standard of care therapy in non-small cell lung cancers (NSCLC); however, a significant number of patient tumors fail to respond, or develop resistance. …”
  18. 538

    Table 7_NK cell-derived extracellular vesicles enhance cytotoxicity and immune cell recruitment in non-small cell lung cancer.xlsx by Joanna Palade (17712960)

    Published 2025
    “…Introduction<p>Immune-based agents, especially Immune Checkpoint Inhibitors (ICI), are standard of care therapy in non-small cell lung cancers (NSCLC); however, a significant number of patient tumors fail to respond, or develop resistance. …”
  19. 539

    Image 1_NK cell-derived extracellular vesicles enhance cytotoxicity and immune cell recruitment in non-small cell lung cancer.jpg by Joanna Palade (17712960)

    Published 2025
    “…Introduction<p>Immune-based agents, especially Immune Checkpoint Inhibitors (ICI), are standard of care therapy in non-small cell lung cancers (NSCLC); however, a significant number of patient tumors fail to respond, or develop resistance. …”
  20. 540

    Table 8_NK cell-derived extracellular vesicles enhance cytotoxicity and immune cell recruitment in non-small cell lung cancer.xlsx by Joanna Palade (17712960)

    Published 2025
    “…Introduction<p>Immune-based agents, especially Immune Checkpoint Inhibitors (ICI), are standard of care therapy in non-small cell lung cancers (NSCLC); however, a significant number of patient tumors fail to respond, or develop resistance. …”